Lumify Reaches Canada As Consumer Health Leads Sales In Bausch + Lomb's Debut Quarter
Executive Summary
Lumify sales grew reported 21% to brand-record $35m in Q2, Bausch + Lomb’s first quarter since separating from Bausch Health through an IPO in May.
You may also be interested in...
Consumer Health Brands Pull Their Weight For Bausch + Lomb To Be ‘Non-Pharma’ Company
Canadian reports Lumify eye, PreserVision, Ocuvite and other OTC drug or supplement brands account for 67% of $646m in vision care business total sales, which was well above half Q2 total revenues of $1.04bn, up 10%.
With ‘Roadmap To Accelerate Growth,’ Saunders Quick Out Of Gate In Return To Bausch + Lomb
“Multi-year plan with three phases, all with measurable, clear objectives” starts with “rewire company for optimal performance” before moving to “innovate and execute” and then to “accelerate growth,” CEO says.
Bausch Health's Securities Litigation Casts Shadow Over B+L's Future As Independent Firm
For all B+L has going for it, including consumer health eye health and vision care products as its sales driver, it could be stymied by investors alleging Bausch Health conducted fraudulent conveyance by spinning out B+L through an IPO in 2022.